Shoulder Innovations, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alan J. Lane
- Full Time Employees
- 300
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 4250 Executive Square La Jolla CA United States of America 92037
- IPO Date
- Jul 31, 2025
- CIK
- 0001699350
- Website
- shoulderinnovations.com
- Similar Companies
- Business
- Shoulder Innovations, Inc. Shoulder Innovations, Inc. (NYSE: SI) is a commercial-stage medical technology company that designs, develops, manufactures, and distributes advanced implant systems for shoulder arthroplasty, including anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (rTSA), primarily in the United States. The company offers its proprietary InSet Glenoid technology, which reduces mechanical stress at the bone-implant interface to enhance fixation, stability, and longevity while addressing the rocking horse effect; InSet Total Shoulder System; InSet Reverse Shoulder System with a lateralized-lateralized design for improved range of motion and fewer complications; InSet 70 humeral stem; ProVoyance Shoulder preoperative planning software; and streamlined Dual Tray and Reverse Tray systems optimized for hospital and ambulatory surgery center efficiency. Founded in 2009 by Dr. Steve Gunther and EDF Ventures and headquartered at 1535 Steele Avenue SW, Suite B, Grand Rapids, Michigan, the company targets orthopedic surgeons and patients requiring shoulder replacement solutions amid a growing $2.8 billion global market. Recent developments include the full commercial launch of the InSet 70 humeral stem in September 2025; a $40 million convertible notes financing closed in July 2025 led by Fidelity Management & Research Company to support commercialization and product development; completion of an initial public offering in July 2025 raising $75 million in gross proceeds; expansion of its surgeon customer base by nearly 50% year-over-year; and third-quarter 2025 revenue growth of 58% to $11.8 million, with full-year guidance raised to $42-44 million representing 33-39% growth.
Wall Street Analysts See a 51.79% Upside in Shoulder Innovations, Inc. (SI): Can the Stock Really Move This High?
Travel + Leisure Co. Breaks Ground on Sports Illustrated Resorts Destination in Tuscaloosa, Alabama
Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Wall Street Analysts Think Shoulder Innovations, Inc. (SI) Could Surge 35.96%: Read This Before Placing a Bet
Shoulder Innovations, Inc. (SI) Q1 2026 Earnings Call Transcript
Shoulder Innovations, Inc. (SI) Reports Q1 Loss, Tops Revenue Estimates
Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
Silicon Metals Corp. Announces Stock Option Grant
Silicon Metals Corp. Announces Private Placement of up to $600,000
Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026
Silicon Metals Corp. Executes Letter of Intent Respecting Mineral Claims in Newfoundland and Labrador
Silicon Metals Corp. Announces Appointment of New Director
Head-To-Head Comparison: Medline (NASDAQ:MDLN) versus Shoulder Innovations (NYSE:SI)
Silicon Metals Corp. Announces Share Consolidation and Record Date
Silicon Metals Corp. Announces Share Consolidation and Director Resignation
Critical Review: Shoulder Innovations (NYSE:SI) and Medline (NASDAQ:MDLN)
Financial Survey: Nanovibronix (NASDAQ:FEED) vs. Shoulder Innovations (NYSE:SI)
Predictive Oncology (NASDAQ:AGPU) and Shoulder Innovations (NYSE:SI) Head-To-Head Contrast
Silicon Metals Corp. Announces Appointment of Mr. Ray Wladichuk to Chief Executive Officer